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Abstract
AURKA (the official symbol for Aurora-A, STK15, or BTAK) regulates the function of centrosomes, spindles, and kinetochores
for proper mitotic progression. AURKA overexpression is observed in various cancers including colon cancer, and a link
between AURKA and chromosomal instability (CIN) has been proposed. However, no study has comprehensively exam-
ined AURKA expression in relation to CIN or prognosis using a large number of tumors. Using 517 colorectal cancers in
two prospective cohort studies, we detected AURKA overexpression (by immunohistochemistry) in 98 tumors (19%). We
assessed other molecular events including loss of heterozygosity (LOH) in 2p, 5q, 17q, and 18q, the CpG island
methylation phenotype (CIMP), and microsatellite instability (MSI). Prognostic significance of AURKA was evaluated by
Cox regression and Kaplan-Meier method. In both univariate and multivariate logistic regressions, AURKA overexpression
was significantly associated with CIN (defined as the presence of LOH in any of the chromosomal segments; multivariate
odds ratio, 2.97; 95% confidence interval, 1.40-6.29; P= .0045). In multivariate analysis, AURKAwas associated with cyclin
D1 expression (P= .010) and inversely with PIK3CAmutation (P= .014), fatty acid synthase expression (P= .028), and family
history of colorectal cancer (P = .050), but not with sex, age, body mass index, tumor location, stage, CIMP, MSI, KRAS,
BRAF, BMI, LINE-1 hypomethylation, p53, p21, β-catenin, or cyclooxygenase 2. AURKAwas not significantly associatedwith
clinical outcome or survival. In conclusion, AURKA overexpression is independently associated with CIN in colorectal can-
cer, supporting a potential role of Aurora kinase-A in colorectal carcinogenesis through genomic instability (rather than epi-
genomic instability).
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Introduction
Chromosomal instability (CIN) in cancer is characterized by frequent
chromosomal abnormalities including translocations, gains, and losses
of chromosomes or their segments. Chromosomal instability promotes
carcinogenesis through loss of tumor suppressors and copy number
gains of oncogenes [1]. Causes of CIN are still poorly understood
but possibly include mitotic spindle checkpoint gene (e.g., BUB1
and BUB1B) deregulation [2], DNA checkpoint gene (e.g., TP53)
mutation [3], cell cycle regulator (e.g., FBXW7) inactivation [4],
telomere dysfunction [5], and abnormal centrosome number and
function [6–8]. Centrosome dysfunction causes abnormal centrosome
segregation during mitosis, which may lead to CIN [6–8].
AURKA (the official symbol for Aurora-A, also known as STK15/
BTAK) is a member of the Aurora family of cell cycle–regulating
serine/threonine kinases and functions in centrosome regulation
and mitotic spindle formation [9,10]. Activation of AURKA in ex-
perimental systems confers malignant phenotype by inducing centro-
some amplification and genomic instability, indicating AURKA as an
oncogene [11–13]. AURKA expression has been reported in various
human cancers [14–20], including colorectal cancers [16]. AURKA
amplification correlates with CIN in colorectal cancer [21]. However,
to our knowledge, no study has comprehensively examined the rela-
tion between AURKA protein overexpression and CIN in colorectal
cancer or whether the relation is independent of other related molecu-
lar features including microsatellite instability (MSI) and the CpG
island methylator phenotype (CIMP).
In this study using a large number (N = 517) of colorectal cancers,
we examined AURKA overexpression in relation to CIN and patient
survival. Because our tumor database included other related molecular
events, we were able to assess whether there was an independent rela-
tion between AURKA and CIN. Our current data support AURKA as
one of potential contributing factors for CIN in colorectal cancer.
Materials and Methods
Study Group
We used the databases of two large prospective cohort studies; the
Nurses’ Health Study (NHS; N = 121,700 women followed since
1976) [22,23], and the Health Professionals Follow-up Study
(HPFS; N = 51,500 men followed since 1986) [23]. Data on height
and weight were obtained by biennial questionnaire. A subset of the
cohort participants developed colorectal cancers during prospective
follow-up. Previous studies on the NHS and HPFS have described
baseline characteristics of cohort participants and incident colorectal
cancer cases and confirmed that our colorectal cancers were good
representatives of a population-based sample [22,23]. Data on tumor
location and stage were obtained through medical record review.
We collected paraffin-embedded tissue blocks from hospitals where
patients had undergone resections of colorectal cancers. On the basis
of availability of adequate tissue specimens and results, a total of
517 colorectal cancers were included. Written informed consent
was obtained from all study subjects. Among our cohort studies,
there was no significant difference in demographic features between
cases with tissue available and those without available tissue [23].
This current analysis represents a new analysis of AURKA on the
existing colorectal cancer database that have been previously charac-
terized for CIMP, MSI, p53, KRAS, BRAF, PIK3CA, long interspersed
nucleotide element 1 (LINE-1), cyclooxygenase 2 (COX-2), and clini-
cal outcome [23–26], which is analogous to novel studies using the
well-described cell lines or animal models. In any of our previous stud-
ies, we have not examined AURKA expression or the relations of
AURKA with clinical outcome and other molecular events. This study
represents a unique novel study in term of 1) a large sample size
analyzed for AURKA; 2) the comprehensive clinical and tissue molec-
ular database used, including the long-term follow-up outcome data,
CIMP, MSI, KRAS, BRAF, PIK3CA, p53, β-catenin, LINE-1 methyla-
tion, and COX-2; and 3) a number of molecular correlates that have
been analyzed. Tissue collection and analyses were approved by the
Harvard School of Public Health and Brigham and Women’s Hospital
Institutional Review Boards.
Histopathologic Evaluations
Hematoxylin and eosin–stained tissue sections were examined by a
pathologist (S.O.) unaware of other data. The tumor grade was cate-
gorized as low (≥50% gland formation) versus high (<50% gland
formation). The presence and extent of extracellular mucin were cate-
gorized as 0% (no mucin), 1% to 49%, or ≥50% of the tumor volume
[27]. The presence and extent of signet ring cells were categorized as
absent (0%) or present (≥1%) [27].
Sequencing of KRAS, BRAF, and PIK3CA
Genomic DNA was extracted from tumor and polymerase chain
reaction (PCR) and Pyrosequencing targeted for KRAS (codons 12 and
13) [28], BRAF (codon 600) [29], and PIK3CA (exons 9 and 20) [30]
were performed as previously described.
Microsatellite Instability Analysis
Microsatellite instability analysis was performed, using 10 micro-
satellite markers (D2S123, D5S346, D17S250, BAT25, BAT26,
BAT40, D18S55, D18S56, D18S67, and D18S487) [27]. MSI-high
was defined as the presence of instability in ≥30% of the markers.
MSI-low was defined as instability in <30% of the markers, and micro-
satellite stable (MSS) tumors were defined as tumors without an un-
stable marker [27].
Loss of Heterozygosity Analysis
For loss of heterozygosity (LOH) analysis using microsatellite markers
(D2S123, D5S346, D17S250, D18S55, D18S56, D18S67, and
D18S487), we duplicated PCR in each sample to exclude allele drop-
outs of one of two alleles [27,31]. Loss of heterozygosity at each locus
was defined as ≥40% reduction of one of two allele peaks in tumor
DNA relative to normal DNA. Chromosomal instability (CIN) pos-
itivity was defined as the presence of LOH in any of the chromosomal
segments among 2p, 5q, 17q, and 18q. CIN negativity was defined as
the absence of LOH in any of the chromosomal segments with the
presence of at least two informative segments.
Real-time PCR for Quantitative DNA Methylation Analysis
Sodium bisulfite treatment on genomic DNA and subsequent real-
time PCR (MethyLight) were validated and performed as previously
described [32].We quantified DNAmethylation in eight CIMP-specific
promoters [CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1,
NEUROG1, RUNX3, and SOCS1] [24,33,34]. CIMP-high was de-
fined as the presence of six or more of eight methylated promoters,
CIMP-low as the presence of one to five of eight methylated promoters,
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and CIMP-0 as the absence of methylated promoters, according to the
previously established criteria [24,35].
Pyrosequencing to Measure LINE-1 Methylation
To accurately quantify relatively high methylation levels in
LINE-1 repetitive elements, we used Pyrosequencing as previously
described [25,36].
Immunohistochemistry for AURKA, p53, p21, Cyclin D1,
β-Catenin, COX-2, and Fatty Acid Synthase
Tissue microarrays were constructed as previously described [23,37].
Methods of immunohistochemical procedures and examples of staining
patterns can be found in the previous reports as follows: p53 [38], p21
(CDKN1A) [39,40], cyclin D1 [41], β-catenin [42], COX-2 [27,43],
and fatty acid synthase (FASN) [27,44]. For AURKA, antigen retrieval
was performed, and deparaffinized tissue sections in Antigen Retrieval
Citra Solution (Biogenex Laboratories, San Ramon, CA) were treated
with microwave in a pressure cooker for 25 minutes. Tissue sections
were incubated with 3% H2O2 (30 minutes) to block endogenous
peroxidase (Dako Cytomation, Carpinteria, CA). A primary antibody
[mouse monoclonal to AURKA (ab13824), 1:100 dilution; Abcam
Inc, Cambridge, MA] was applied, and the slides were maintained
at 4°C overnight, followed by mouse secondary antibody (Vector
Laboratories, Burlingame, CA) for 60 minutes, an avidin-biotin com-
plex conjugate (Vector Laboratories) for 60 minutes, diaminobenzidine
(5 minutes) and methyl-green counterstain. Nuclear AURKA expres-
sion was recorded as no expression, weak expression, moderate expres-
sion, or strong expression (Figure 1). AURKA overexpression was
defined as moderate to strong expression in any portion of tumor cells
or at least 50% of tumor cells with weak staining. Appropriate posi-
tive and negative controls were included in each run of immunohisto-
chemistry. Each immunohistochemical maker was interpreted by one of
the investigators (AURKA by Y.B.; cyclin D1 and β-catenin by K.N.;
p53, p21, COX-2, and FASN by S.O.) unaware of other data. A ran-
dom selection of 117 cases was examined for AURKA by a second
observer (K.S.) unaware of other data, and concordance between the
two observers was 0.85 (κ = 0.62, P < .0001), indicating substantial
agreement. For each of the other immunohistochemical markers, a
second observer (S.O. for β-catenin; K.S. for cyclin D1 and p21;
K.N. for p53, COX-2, and FASN) examined a random selection of
more than 100 tumors unaware of other data, and the concordance
rate between the two observers was always greater than 0.82 [all κ >
0.61 (except for FASN, κ = 0.57), all P < .0001], indicating generally
substantial agreement.
Statistical Analysis
All statistical analyses used SAS program (Version 9.1; SAS Institute,
Cary, NC). All P values were two-sided, and statistical significance
was set at P ≤ .05. For categorical data, the χ2 test was performed,
and odds ratio (OR) with 95% confidence interval (CI) was com-
puted. To compare mean LINE-1 methylation levels, the t test assum-
ing unequal variances was performed. The κ coefficient was calculated
to assess an agreement between the two interpreters in immunohisto-
chemical analyses. To assess independent relations of AURKA over-
expression with CIN, a multivariate logistic regression analysis was
performed. Odds ratio was adjusted for sex, age (continuous), body
mass index (BMI, <30 vs ≥30 kg/m2), family history of colorectal can-
cer (present vs absent), tumor location (right colon vs left colon vs rec-
tum), tumor stage (I-II vs III-IV), tumor grade (low vs high), mucinous
component (0 vs ≥1%), signet ring cell component (0 vs ≥1%), CIMP
status (high vs CIMP-low/0), MSI status (high vs low/MSS), LINE-1
methylation (continuous), BRAF, KRAS, PIK3CA, p53, p21, cyclin D1,
β-catenin, COX-2, and FASN.
For survival analysis, Kaplan-Meier method was used to assess sur-
vival time distribution according to AURKA status, and log-rank test
was used to test significance of a deviation from the null hypothesis.
For the analyses of colorectal cancer–specific mortality, death as a
result of colorectal cancer was the primary end point and deaths as
a result of other causes were censored. To assess independent effect of
AURKA on mortality, we constructed a multivariate, stage-matched
conditional Cox proportional hazard model to compute a hazard
ratio (HR) according to AURKA status, adjusted for sex, age, year of
diagnosis (continuous), BMI, family history of colorectal cancer, tumor
location, stage, grade, CIMP,MSI, CIN, BRAF,KRAS, PIK3CA, LINE-1
methylation, p53, p21, cyclin D1, β-catenin, COX-2, and FASN.
Results
AURKA Overexpression in Colorectal Cancer
Among the 517 colorectal cancers in this study, 98 (19%) showed
nuclear AURKA overexpression (i.e., AURKA-positive; Figure 1).
Table 1 shows the frequencies of AURKA overexpression according to
Figure 1. AURKA (Aurora-A) expression in colorectal cancer cells.
(A) Negative for nuclear AURKA overexpression in colorectal cancer
cells (arrow). Inflammatory cells serve as an internal positive control
for AURKA positivity (white arrow). (B) Positive for nuclear AURKA
overexpression in colorectal cancer cells (arrowheads).
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various clinical and pathologic features. AURKA overexpression was in-
versely associated with family history of colorectal cancer (OR, 0.49;
95% CI, 0.26-0.89; P = .018).
AURKA, CIN, and Other Molecular Features in
Colorectal Cancer
Table 2 summarizes the frequencies of AURKA overexpression
according to status of CIN and other molecular features in colorectal
cancer. Chromosomal instability (CIN) was defined as the presence of
LOH in any of the chromosomal segments among 2p, 5q, 17q, and
18q. AURKA overexpression was significantly associated with CIN
(OR, 2.17; 95% CI, 1.09-4.32; P = .024).
AURKA overexpression was inversely associated with KRAS muta-
tion (OR, 0.56; 95% CI, 0.35-0.92; P = .021), PIK3CA mutation
(OR, 0.25; 95% CI, 0.09-0.71; P = .0050), and β-catenin activation
(OR, 0.60; 95% CI, 0.36-0.99; P = .046; Table 2).
Multivariate Analysis to Assess Independent Relations
with AURKA
We performed multivariate logistic regression analysis to examine
whether AURKA was independently associated with CIN (Table 3).
AURKA overexpression was significantly associated with CIN (multi-
variate OR 2.97; 95% CI, 1.40-6.29; P = .0045) independent of other
variables. In addition, AURKA seemed to be associated with cyclin D1
Table 1. Frequency of AURKA Overexpression in Colorectal Cancer.
Clinical or Pathologic Feature Total N AURKA (+) Univariate OR (95% CI) P
All cases 517 98 (19%)
Gender
Men 203 35 (17%) 1
Women 314 63 (20%) 1.20 (0.76-1.90)
Age (years)
≤59 118 20 (17%) 1
60-69 233 43 (18%) 1.10 (0.62-1.99)
≥70 166 35 (21%) 1.31 (0.71-2.41)
BMI (kg/m2)
<25 209 43 (21%) 1
25-30 192 36 (19%) 0.89 (0.54-1.46)
≥30 87 12 (14%) 0.62 (0.31-1.24)
Family history of colorectal cancer
(−) 396 84 (21%) 1 Referent
(+) 121 14 (12%) 0.49 (0.26-0.89) .018
Tumor location
Right colon (cecum
to transverse colon)
243 53 (22%) 1
Left colon (splenic
flexure to sigmoid)
165 25 (15%) 0.64 (0.38-1.08)
Rectum 89 14 (16%) 0.66 (0.35-1.28)
Stage
I 106 18 (17%) 1
II 158 30 (19%) 1.14 (0.60-2.18)
III 138 19 (14%) 0.78 (0.39-1.57)
IV 71 15 (21%) 1.31 (0.61-2.81)
Tumor grade
Low 456 82 (18%) 1
High 45 11 (24%) 1.48 (0.72-3.03)
Mucinous component
0% 267 43 (16%) 1
1%-49% 116 27 (23%) 1.58 (0.92-2.71)
≥50% 64 16 (25%) 1.74 (0.90-3.34)
Signet ring cell component
0% 387 72 (19%) 1
≥1% 29 7 (24%) 1.39 (0.57-3.38)
Only significant P values are described.
Table 2. Frequency of AURKA Overexpression in Colorectal Cancer According to
Various Molecular Features.
Molecular Feature Total N AURKA (+) Univariate OR (95% CI) P
CIN*
(−) 105 11 (10%) 1 Referent
(+) 291 59 (20%) 2.17 (1.09-4.32) .024
CIMP status (no. of methylated CIMP markers)
CIMP-0 (0) 224 43 (19%) 1
CIMP-low (1-5) 202 30 (15%) 0.73 (0.44-1.22)
CIMP-high (6-8) 77 21 (27%) 1.58 (0.86-2.88)
MSI status
MSS 376 66 (18%) 1
MSI-low 52 11 (21%) 1.26 (0.62-2.58)
MSI-high 87 21 (24%) 1.49 (0.86-2.61)
BRAF mutation
(−) 437 80 (18%) 1
(+) 67 17 (25%) 1.51 (0.83-2.77)
KRAS mutation
(−) 327 72 (22%) 1 Referent
(+) 189 26 (14%) 0.56 (0.35-0.92) .021
PIK3CA mutation
(−) 397 86 (22%) 1 Referent
(+) 62 4 (6%) 0.25 (0.09-0.71) .0050
LINE-1 methylation
≥70% 61 9 (15%) 1
50%-70% 360 66 (18%) 1.30 (0.61-2.76)
<50% 76 19 (25%) 1.93 (0.80-4.63)
p53 expression
(−) 311 67 (22%) 1
(+) 202 31 (15%) 0.66 (0.41-1.05)
p21
Expressed 104 24 (23%) 1
Lost 403 73 (18%) 0.73 (0.44-1.24)
Cyclin D1 expression
(−) 142 21 (15%) 1
(+) 349 75 (21%) 1.57 (0.93-2.68)
β-Catenin†
Inactive (score 0-2) 294 62 (21%) 1 Referent
Active (score 3-5) 175 24 (14%) 0.60 (0.36-0.99) .046
COX-2 expression
(−) 90 23 (26%) 1
(+) 426 74 (17%) 0.61 (0.36-1.05)
FASN expression
(−) 350 70 (20%) 1
(+) 65 7 (11%) 0.48 (0.21-1.10)
*Chromosomal instability was defined as the presence of LOH in any of the chromosomal
segments among 2p, 5q, 17q, and 18q.
†β-Catenin activation score is based on the method previously described [72].
Table 3. Multivariate Logistic Regression to Show Independent Relationship between
CIN and AURKA Overexpression in Colorectal Cancer.
Variable Independently Associated
with AURKA
Multivariate OR (95% CI) P
CIN* 2.97 (1.40-6.29) .0045
Other significant variables
PIK3CA mutation 0.24 (0.08-0.70) .010
Cyclin D1 expression 1.93 (1.15-3.24) .012
FASN expression 0.37 (0.15-0.92) .032
Family history of colorectal cancer 0.50 (0.26-0.96) .036
The multivariate logistic regression model included age, sex, BMI, tumor location, stage,
grade, mucinous component, signet ring cells, CIMP, MSI, KRAS, BRAF, LINE-1 methyl-
ation, p53, p21, β-catenin, COX-2, FASN, and the variables listed in the table. Only signif-
icant variables are listed.
*Chromosomal instability was defined as the presence of LOH in any of the chromo-
somal segments among 2p, 5q, 17q, and 18q.
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expression (P = .012) and inversely with PIK3CAmutation (P = .010),
FASN expression (P = .032), and family history of colorectal cancer
(P = .036; Table 3); however, considering multiple hypotheses testing
and these P values between .05 and .01, any of these additional asso-
ciations might simply be a chance event.
AURKA and Patient Survival
We assessed the influence of AURKA overexpression on clinical
outcome of patients with stage I to IV colorectal cancer and adequate
follow-up. We have previously shown that clinical outcome data in
our two independent cohort studies are valid and reliable in detecting
significant molecular predictors of patient survival [25,26,43,44].
There were a total of 216 deaths, including 124 colorectal cancer–
specific deaths. In Kaplan-Meier analysis, AURKA was not signifi-
cantly associated with colorectal cancer–specific (log rank, P = .67)
or overall survival (log rank, P = .78). We also performed Cox regres-
sion analysis to assess patient mortality according to AURKA status
(Table 4). For both cancer-specific and overall mortality, AURKA
overexpression was not significantly related with patient outcome
in univariate analysis, stage-matched analysis, or multivariate analy-
sis. When we assessed patients with colon cancers, AURKA remained
unrelated with patient mortality.
Discussion
We conducted this study to examine the relationship between
AURKA overexpression and CIN in colorectal cancer. In addition,
we assessed the relationship of AURKA with clinical, pathologic,
and other molecular features and with patient survival. We found that
AURKA was associated with CIN, independent of any of the clinical,
pathologic, and molecular variables examined. Our rich tumor data-
base allowed us to examine whether there is an independent relation-
ship of AURKA with CIN as well as with clinical outcome. Our data
support the hypothesis that AURKA overexpression is one of the con-
tributing factors for CIN during colorectal cancer development.
Studying molecular alterations is important in cancer research [45–
56]. Our resource of a large number (N = 517) of colorectal cancers
derived from the two independent prospective cohort studies has en-
abled us to precisely estimate the frequency of colorectal cancers with a
specific molecular feature (such as AURKA overexpression, MSI, etc.).
The large number of cases has also provided us with a sufficient power
in the multivariate logistic regression analysis and survival analysis.
Thus, in survival analysis, we can conclude that AURKA expression
is not significantly associated with patient survival.
Accumulating evidence suggests that AURKA activation is related to
cancer development through CIN [11–13,57]. AURKA is mainly lo-
calized at spindle poles and the mitotic spindle during mitosis, where it
regulates the function of centrosomes, spindles, and kinetochores, all
of which are required for proper mitosis progression [9,10]. AURKA
protein expression has also been related with TERT (telomerase) activ-
ity, thus possibly related with telomere function [16]. AURKA gene
amplification [58,59] and AURKA gene overexpression [58] have been
reported in colorectal cancer. Another study using colon cancer cell
lines and a small number (N = 48) of human colorectal cancer tissues
has shown that high copy number of AURKA is associated with CIN
and AURKA protein overexpression [21]. However, the discrepancy in
the frequencies of AURKA amplification and AURKA protein over-
expression has been reported in several other cancers [13,19,60]. To
the best of our knowledge, a significant relationship between AURKA
protein overexpression and CIN has not been shown using a large
number of colorectal cancer tissues. Molecular correlates with AURKA
protein overexpression are important for the better understanding of
genetic and epigenetic alterations during the colorectal carcinogenic
process, especially in relation to CIN.
It remains controversial whether AURKA expression level correlates
with malignant phenotype or patient prognosis in human cancers.
Studies on several types of human cancers have indicated that AURKA
overexpression may be related with poor prognosis [15,17,18,61] or
with higher recurrence rate [62]. However, other studies have shown
that AURKA expression is not associated with patient prognosis
[20,63]. Another study has shown that activation of AURKA is asso-
ciated with an early stage disease in ovarian cancer [19]. In a previous
study on colorectal cancer (N = 200) [16], AURKA overexpression
was associated with high-grade tumor, but the relationship between
AURKA and clinical outcome was unclear. In our current study (N =
517), AURKA overexpression was not associated with tumor grade.
This discrepancy might be due to a difference in the patient cohorts
or the methods to assess AURKA overexpression or simply due to a
chance variation between different studies. In addition, our analysis
found that AURKA overexpression was not associated with prognosis
of patients with stage I to IV colorectal cancer. Our findings suggest
that AURKA overexpression may not mark an aggressive type of colo-
rectal cancer.
Interestingly, we did observe inverse relations between AURKA
and PIK3CA mutation as well as FASN expression in colorectal can-
cer, independent of clinical, pathologic, and other molecular vari-
ables. In various cancers including colorectal cancer, mutant PIK3CA
stimulates the PI3K-AKT signaling pathway [64]. Fatty acid synthase
overexpression has been associated with the PI3K-AKT pathway
Table 4. AURKA Expression and Patient Mortality in Colorectal Cancer.
Total N Cancer-Specific Mortality Overall Mortality
Deaths/Person-Years Univariate HR
(95% CI)
Stage-matched HR
(95% CI)
Multivariate HR
(95% CI)
Deaths/Person-Years Univariate HR
(95% CI)
Stage-matched HR
(95% CI)
Multivariate HR
(95% CI)
Colon and rectal cancers
AURKA (−) 398 103/3180 1 (referent) 1 (referent) 1 (referent) 179/3180 1 (referent) 1 (referent) 1 (referent)
AURKA (+) 89 21/688 0.90 (0.57-1.45) 0.98 (0.60-1.60) 0.97 (0.57-1.65) 37/688 0.95 (0.67-1.36) 1.00 (0.69-1.45) 1.03 (0.69-1.53)
Colon cancers
AURKA (−) 324 78/2648 1 (referent) 1 (referent) 1 (referent) 144/2648 1 (referent) 1 (referent) 1 (referent)
AURKA (+) 75 19/569 1.07 (0.65-1.77) 1.13 (0.66-1.93) 0.89 (0.49-1.60) 31/569 0.99 (0.67-1.46) 1.00 (0.66-1.50) 0.99 (0.63-1.55)
The multivariate, stage-matched conditional Cox model included sex, age, year of diagnosis (continuous), BMI, family history of colorectal cancer, tumor location, stage, grade, CIMP, MSI,
CIN, BRAF, KRAS, PIK3CA, LINE-1 methylation, p53, p21, cyclin D1, β-catenin, COX-2, and FASN.
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activation in some cancers [65,66]. A study using human cancer cell
lines [67] has shown that AKT is likely responsible for the up-regulation
of AURKA for mitotic progression. In contrast, another study using
mouse oocytes [68] has shown that the activation of AURKA on
microtubule-organizing centers is independent of the PI3K-AKT path-
way. As to the relationship between AURKA and the PI3K-AKT path-
way, further studies are needed. We also demonstrated that AURKA
overexpression was associated with nuclear cyclin D1 expression. A
previous study using a mouse model [11] has reported that AURKA
overexpression cause nuclear accumulation of cyclin D1, which is in
agreement with our current data.
Recently, Aurora kinases have been targeted for cancer therapy,
and a new class of drugs known as Aurora kinase inhibitors has been
undergoing preclinical and clinical assessments [69,70]. Among
them, VX-680 has shown promising results in animal studies, in-
hibiting tumor growth in a range of xenograft models and leading
to regression of colon tumor [71]. VX-680 is already undergoing
the clinical study, but there is no biomarker for selecting patients
to benefit for clinical trials of this drug. Hereafter, AURKA expres-
sion in the resected specimens might attract increasing attention as a
biomarker for patient selection. In this respect, our findings may
have clinical implications.
In particular, a possible inverse relation between AURKA and family
history of colorectal cancer merits discussion. An association between
a molecular change and family history of colorectal cancer implies a
genetic factor (and/or a shared environmental factor) that may con-
tribute to the development of the given molecular change. The inverse
association between AURKA and family history likely supports genetic
predisposition to molecular changes (such as MSI) alternative to the
AURKA-CIN pathway. Clarification of this issue by future research
is important considering AURKA inhibitors as potential targeted ther-
apy against colorectal cancers, including familial cases.
In conclusion, using a large number of colorectal cancers, we have
shown that AURKA overexpression is independently associated with
CIN. Our data support the hypothesis that AURKA may contribute
to colorectal carcinogenesis through CIN.
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